Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Yin

Showing results (51-60 of 59) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 59 results.
The Lancet. HIV|August 4, 2023
Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1-2 dose-confirmation studyKristina M Brooks, Jennifer J Kiser, Lauren Ziemba, et al.
The Lancet. HIV|March 6, 2025
Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding studyCarolyn Bolton Moore, Kristin Baltrusaitis, Brookie M Best, et al.
Science Translational Medicine|July 5, 2023
Broadly neutralizing antibody treatment maintained HIV suppression in children with favorable reservoir characteristics in BotswanaRoger L Shapiro, Gbolahan Ajibola, Kenneth Maswabi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 8, 2022
Multicenter Prospective Study of Biomarkers for Diagnosis of Invasive Candidiasis in Children and AdolescentsBrian T Fisher, Craig L K Boge, Rui Xiao, et al.
Science Translational Medicine|May 6, 2026
VRC01 with antiretroviral initiation in infants is well tolerated, and higher concentrations associate with greater HIV-1 DNA declinesAlka Khaitan, Jane C Lindsey, Edmund V Capparelli, et al.
Blood Advances|May 28, 2025
Infection after CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: real-world analysis from CIBMTRKitsada Wudhikarn, Megan M Herr, Min Chen, et al.
Journal of the Pediatric Infectious Diseases Society|November 8, 2024
Transition to Enteral Triazole Antifungal Therapy for Pediatric Invasive Candidiasis: Secondary Analysis of a Multicenter Cohort Study Conducted by the Pediatric Fungal NetworkRobert F T Bucayu, Craig L K Boge, Inci Yildirim, et al.
Journal of the Pediatric Infectious Diseases Society|August 10, 2021
Comparative Effectiveness of Echinocandins vs Triazoles or Amphotericin B Formulations as Initial Directed Therapy for Invasive Candidiasis in Children and AdolescentsBrian T Fisher, Theoklis E Zaoutis, Rui Xiao, et al.
Journal of the Pediatric Infectious Diseases Society|August 17, 2023
Adjunctive Diagnostic Studies Completed Following Detection of Candidemia in Children: Secondary Analysis of Observed Practice From a Multicenter Cohort Study Conducted by the Pediatric Fungal NetworkRachel L Wattier, Robert F T Bucayu, Craig L K Boge, et al.
Pageof 6

Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
The Lancet. HIV|August 4, 2023
Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1-2 dose-confirmation studyKristina M Brooks, Jennifer J Kiser, Lauren Ziemba, et al.
The Lancet. HIV|March 6, 2025
Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding studyCarolyn Bolton Moore, Kristin Baltrusaitis, Brookie M Best, et al.
Science Translational Medicine|July 5, 2023
Broadly neutralizing antibody treatment maintained HIV suppression in children with favorable reservoir characteristics in BotswanaRoger L Shapiro, Gbolahan Ajibola, Kenneth Maswabi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 8, 2022
Multicenter Prospective Study of Biomarkers for Diagnosis of Invasive Candidiasis in Children and AdolescentsBrian T Fisher, Craig L K Boge, Rui Xiao, et al.
Science Translational Medicine|May 6, 2026
VRC01 with antiretroviral initiation in infants is well tolerated, and higher concentrations associate with greater HIV-1 DNA declinesAlka Khaitan, Jane C Lindsey, Edmund V Capparelli, et al.
Blood Advances|May 28, 2025
Infection after CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: real-world analysis from CIBMTRKitsada Wudhikarn, Megan M Herr, Min Chen, et al.
Journal of the Pediatric Infectious Diseases Society|November 8, 2024
Transition to Enteral Triazole Antifungal Therapy for Pediatric Invasive Candidiasis: Secondary Analysis of a Multicenter Cohort Study Conducted by the Pediatric Fungal NetworkRobert F T Bucayu, Craig L K Boge, Inci Yildirim, et al.
Journal of the Pediatric Infectious Diseases Society|August 10, 2021
Comparative Effectiveness of Echinocandins vs Triazoles or Amphotericin B Formulations as Initial Directed Therapy for Invasive Candidiasis in Children and AdolescentsBrian T Fisher, Theoklis E Zaoutis, Rui Xiao, et al.
Journal of the Pediatric Infectious Diseases Society|August 17, 2023
Adjunctive Diagnostic Studies Completed Following Detection of Candidemia in Children: Secondary Analysis of Observed Practice From a Multicenter Cohort Study Conducted by the Pediatric Fungal NetworkRachel L Wattier, Robert F T Bucayu, Craig L K Boge, et al.
Pageof 6